{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066945","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.214430+00:00","generated_at":"2026-05-22T04:41:18.459203+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alector Q1 net loss $40.5M ($0.41/sh); INFRONT-3 data on track for Q4 2025","bullets":["Net loss of $40.5M ($0.41/sh) vs $36.1M ($0.38/sh) in Q1 2024; collaboration revenue $3.7M (down from $15.9M).","Cash, cash equivalents, and investments total $354.6M as of March 31, 2025; runway extended into second half of 2027.","Topline INFRONT-3 Phase 3 data for latozinemab in FTD-GRN expected in Q4 2025; enrollment complete in PROGRESS-AD Phase 2 for AL101.","Giacomo Salvadore appointed Chief Medical Officer; 2025 guidance reiterated: R&D $175-185M, G&A $55-65M, collab rev $5-15M.","Advancing preclinical Alector Brain Carrier programs including anti-amyloid beta antibody and GCase enzyme replacement therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066945","json":"https://secwatch.observer/filing/0000950170-25-066945.json","markdown":"https://secwatch.observer/filing/0000950170-25-066945.md","text":"https://secwatch.observer/filing/0000950170-25-066945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017025066945/0000950170-25-066945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017025066945/alec-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:41:18.459203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}